EU says new legislation driven growing concerns over patient access to new medicines and security of supply
Pharmaceutical companies say new EU rules on drug development will mean Europe loses out on the research and development of new medicines. Photograph: iStockrules on drug development will see Europe lose out on the research and development of new medicines, a report compiled for the industry says.
The Efpia report, compiled by the Dolon consultancy, says the proposed changes would reduce the incentive for companies to invest in new medicines in Europe by 55 per cent over the next 15 years. Regulatory data protection kicks in only from the moment a medicine is actually approved for marketing. In the EU currently, it lasts for eight years from that point: the proposed legislation reduces this to six, although the term can be extended under certain circumstances.
The EU says it needs to act as patient access to medicinal products across the EU and security of supply are growing concerns. Restricted budgets and the high price of new medicines — especially more modern high-tech drugs and those targeting small patient populations – have become a headline issue in Europe with high-profile campaigning against profit margins charged by drug companies.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US earnings season proving a mixed bagCompanies are beating estimates but warning of weak demand ahead
Read more »
Cap decision could prevent 2024 flight reductionThe operator of Dublin Airport has said if a decision on increasing the cap on passenger numbers is made quickly, it could prevent the number of flights in and out of the airport in 2024 and 2025 from being reduced.
Read more »
Protection from deportation among new measures to combat human traffickingGovernment will also order a review of missing children cases to determine if they are linked to trafficking
Read more »
How activist investors can create chaos – or huge profitsEuropean and Irish companies are increasingly being targeted by investors looking to drive strategic change and grow their bottom line
Read more »
'A Diamond in the Rough' with Steven van BelleghemDespite high aspirations to delight customers, many companies falter at the execution stage, leaving a gap between grand plans and customer realities. Steven...
Read more »